Catalyst Dossier · compiled by Celia 🧫

Eli Lilly and Company (LLY)

Pharmaceutical Preparations · market cap $1034.6B · as of 2026-06-23

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-08-06

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Eli Lilly and Company (LLY) is a $1.03 trillion market-cap multinational pharmaceutical company with ~50,000 employees and products sold in ~125 countries. The company has posted explosive revenue growth — from $28.3B in 2021 to $65.2B in 2025 — driven largely by its GLP-1/incretin franchise, and carries a dense near-term catalyst calendar headlined by Phase 3 readouts for Retatrutide (obesity) and Orforglipron (oral GLP-1) in late 2026 and early 2027. Net debt stands at $38.1B against $5.3B cash, reflecting aggressive capital deployment into manufacturing and pipeline expansion.

The catalyst path

2026-08-06Earningsimp 5/10
2026-10-15 (est.)Phase 3 · pemetrexedimp 9/10
2026-11-15 (est.)Phase 2 · LY3938577imp 7/10
2026-11-15 (est.)Phase 3 · Lasmiditanimp 9/10
2026-12-15 (est.)Phase 2 · LY3537021imp 7/10
2026-12-15 (est.)Phase 3 · Retatrutideimp 9/10
2027-01-15 (est.)Phase 3 · Orforglipronimp 9/10
2027-02-15 (est.)Phase 3 · Orforglipronimp 9/10

Pipeline

Asset	Phase	Indication
somatropin, rDNA origin, for injection	Phase 3	Growth Disorder
Retatrutide	Phase 3	Obesity
Ultra-Rapid Lispro	Phase 3	Type 1 Diabetes Mellitus
Erbitux (Cetuximab)	Phase 2	Colorectal Neoplasms
Atomoxetine Hydrochloride	Phase 3	Attention Deficit Hyperactivity Disorder
Duloxetine	Phase 3	Urinary Stress Incontinence
LY2216684	Phase 3	Major Depressive Disorder
Insulin Efsitora Alfa	Phase 3	Type 2 Diabetes
Abemaciclib	Phase 3	Breast Cancer
LY2140023	Phase 2	Schizophrenia
LY3209590	Phase 2	Type 2 Diabetes Mellitus
LY3819253	Phase 3	COVID-19
LY900014	Phase 3	Type 1 Diabetes Mellitus
Gemcitabine	Phase 3	Non-Small Cell Lung Cancer
Ixekizumab Auto-Injector	Phase 3	Plaque Psoriasis
pemetrexed	Phase 3	Non-Small Cell Lung Cancer
Erlotinib	Phase 3	Non Small Cell Lung Cancer
GEMZAR	Phase 3	Pancreatic Neoplasms
Dulaglutide	Phase 3	Type 2 Diabetes Mellitus
IMC-1121B (ramucirumab)	Phase 2	Carcinoma, Non-Small-Cell Lung

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by Celia. The catalyst path & pipeline above are free.

See Pro

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by Celia. Not financial advice.